Deltex Medical Group (LON:DEMG) has raised £2.67mln in total through a recent funding after its open offer received a 57% take up.
Proceeds will be used to repay a £1mln convertible loan note in full to Amati.
Deltex has focused its recent sales efforts on the US as a cash squeeze has seen lower demand from the NHS for its blood flow monitoring systems.
Operating cash break-even is now expected during 2016 through a combination of US expansion, product development and international sales growth along with cash generated from a pared down UK operation.